Risk & Volatility
Carmell has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 4.02, indicating that its stock price is 302% more volatile than the S&P 500.
Insider & Institutional Ownership
24.2% of Carmell shares are held by institutional investors. Comparatively, 6.9% of Arch Therapeutics shares are held by institutional investors. 29.0% of Carmell shares are held by insiders. Comparatively, 4.5% of Arch Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Carmell and Arch Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carmell | N/A | -217.50% | -50.22% |
| Arch Therapeutics | -8,257.70% | N/A | -730.22% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carmell | $32,839.00 | 348.22 | -$15.44 million | ($0.46) | -1.19 |
| Arch Therapeutics | $80,000.00 | 0.00 | -$6.98 million | ($2.34) | N/A |
Arch Therapeutics has higher revenue and earnings than Carmell. Carmell is trading at a lower price-to-earnings ratio than Arch Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Carmell beats Arch Therapeutics on 5 of the 9 factors compared between the two stocks.
About Carmell
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
About Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.
